Medical costs after initiation of drug treatment for overactive bladder: Effects of selection bias on cost estimates

American Journal of Managed Care

Volumn 11, Issue SUPPL. 4, 2005, Pages

  Nitz, Nicole M ^a   Jumadilova, Zhanna ^a   Darkow, Theodore ^a   Frytak, Jennifer R ^a   Bavendam, Tamara ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG COST; DRUG SELECTIVITY; GENDER; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; HUMAN TISSUE; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MEDICAL LIABILITY; OVERACTIVE BLADDER; PRESCRIPTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; COHORT STUDIES; CRESOLS; DELAYED-ACTION PREPARATIONS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RETROSPECTIVE STUDIES; SELECTION BIAS; UNITED STATES; URINARY INCONTINENCE;

EID: 22544461030     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-336.
2. Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Zhou SZ, Hunt T. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61:1123-1128.
3. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63: 461-465.
4. Zhou Z, Jensen G. Insurance claim costs for overactive bladder disorder. Drug Benefit Trends. 2001;13:45-48.
5. Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care. 2002;8(19 suppl):S598-S607.
6. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 suppl):574-579.
7. Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005;25:511-519.
8. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: clinical applications. JAMA. 2004;291:996-999.
9. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. JAMA. 2004; 291:986-995.
10. Elliott DS, Lightner DJ, Blute ML. Medical management of overactive bladder. Mayo Clin Proc. 2001;76: 353-355.
11. Assessment and treatment of urinary incontinence. Scientific Committee of the First International Consultation on Incontinence. Lancet. 2000;355:2153-2158.
12. Sarkar PK, Ritch AE. Management of urinary incontinence. J Clin Pharm Ther. 2000;25:251-263.
13. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol. 2004;22:251-256.
14. Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004;3:46-53.
15. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003;326:841-844.
16. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78: 687-695.
17. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002;50:799-807.
18. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin. 2002;18:177-184.
19. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76:358-363.
20. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10:283-289.
21. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50:90-96.
22. Boone TB, Kusek JW, Nyberg LM, et al. Treatment patterns and associated symptom improvement during six months of care for overactive bladder: a prospective, observational study. Clin Ther. 2002;24: 397-408.
23. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760-766.
24. Noe L, Becker R, Williamson T, Chen D. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm. 2002;8:343-352.
25. Hall JA, Nelson MA, Meyer JW, Williamson T, Wagner S. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. Manag Care Interface. 2001; 14:69-75.
26. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000;20:470-475.
27. Malone DC, Okano GJ. Treatment of urge incontinence in Veterans Affairs medical centers. Clin Ther. 1999;21:867-877.
28. Schneeweiss R, Rosenblatt RA, Cherkin DC, Kirkwood CR, Hart G. Diagnosis clusters: a new tool for analyzing the content of ambulatory medical care. Med Care. 1983;21:105-122.
29. Kennedy PE. Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Econ Rev. 1981;71:801.
30. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrics. 1980;48:817-830.
31. White H. Maximum likelihood estimation of misspecified models. Econometrica. 1982;50:1-25.
32. Laupacis A, Mamdani M. Observational studies of treatment effectiveness: some cautions. Ann Intern Med. 2004;140:923-924.
33. Nitz N, Jumadilova Z, Meyer J, Bavendam T. Implications of overactive bladder ICD-9-CM code changes and use of codes in a managed care population. Presented at: International Society of Pharmacoeconomics and Outcomes Research; October 24-26, 2004; Hamburg, Germany.